Title
Post acute CoViD-19 syndrome (PACS) - Long CoViD
Authors
Francesco Chiappelli* & Lily Fotovat
Affiliation
Center for the Health Sciences, UCLA, Los Angeles, USA;
Dental Group of Sherman Oaks, CA 91403, USA; *Corresponding author:
Francesco Chiappelli - E-mail: Chiappelli.research@gmail.com
Lily Fotovat - E-mail: lilyfotovat@gmail.com
Article Type
Editorial
Date
Received October 8, 2022; Accepted October 18, 2022, Published October 31, 2022
Abstract
Patients sero-positive for the Systemic Acute Respiratory Syndrome Corona virus2 (SARS-CoV2) virus develop the Corona Virus Disease 2019 (CoViD-19). CoViD-19 may be asymptomatic in some individuals, proffer mild symptoms in other patients, and can be a serious and even lethal disease in a sub-group of the population. The variables that determine the severity of CoViD-19 have not been fully characterized. What is clear is that the patients who survive CoViD-19 return to a state of sero-negativity for SARS-CoV2 generally within 3-5 weeks. However, several cases of repeated infection have been reported, and a large proportion of CoViD-19-recovered patients manifest multi-system and multi-organ symptomatic pathologies several weeks-to-months after resuming sero-negativity for SARS-CoV2. This new pathological condition, originally termed Long Covid, is now recognized as the Post Acute CoViD-19 Syndrome (PACS). The original principal clusters of signs and symptoms of PACS: likelihood of relapse and reinfection, physical fatigue and cognitive slowdown, may actually be broadened to include immune deregulation, cardiovascular disease and coagulation abnormalities. The development and evaluation of new and improved clinical interventions for PACS are critical and timely.
Keywords
Coronavirus (CoV), Middle-East Respiratory Syndrome (MERS); Severe Acute Respiratory Syndrome (SARS), Systemic Acute Respiratory Syndrome Corona virus2 (SARS-CoV2), World Health Organization (WHO), Center for Disease Control (CDC), Corona Virus Disease 2019 (CoViD-19), Angiotensin-converting enzyme (ACE), exhausted T cells (Tex), interleukin (IL), tumor necrosis factor (TNF), Post‐COVID‐related osteonecrosis of the jaw (PC‐RONJ), Post Acute CoViD-19 Syndrome (PACS)
Citation
Chiappelli & Fotovat, Bioinformation 18(10): 908-911 (2022)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
